1 / 15

Objectives

MANAGEMENT AND OUTCOME OF PATIENTS WITH HEPATIC ENCEPHALOPATHY WITH SPECIAL EMPHASIS ON FLUMAZENIL.

rae
Download Presentation

Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MANAGEMENT AND OUTCOME OF PATIENTS WITH HEPATIC ENCEPHALOPATHY WITH SPECIAL EMPHASIS ON FLUMAZENIL Author:Jaimin Patel (III year resident), K.M. Mehariya (Associate professor) DEPARTMENT OF PAEDIATRICS M. P. SHAH MEDICAL COLLEGE, JAMNAGAR, GUJARAT

  2. Objectives • To know the incidence of hepatic encephalopathy in hospital admission. • To assess the clinical staging • To find out possible etiology. • To observe the role of Flumazenil therapy. • To know the outcome.

  3. Material and Method

  4. Stages

  5. Treatment

  6. Flumazenil One of mech of Hepatic encephalopathy is Increased endogenous Benzodiazepines Mech : Flumazenil competitively antagonizes Benzodiazepines Metabolism: liver, Half life : 1 hr. Duration : 30 to 60 min. Dose : 0.01 mg/kg (max dose :0.2 mg) than 0.005-0.01 mg/kg (max dose : 0.2mg) given every Q 1minute to max total cumulative dose of 1 mg. Doses may be repeated in 20 minutes up to max of 3 mg in 1 hr.

  7. Observation and Results.................

  8. Incidence 1.87/1000

  9. Age: 3.4 years average Sex: M:F :: 1.4:1 Etiology:

  10. Stages

  11. Complications

  12. Investigations Urine Bile salts Bile pigments: 27/29 Serum Bilirubin: 8.6 average PT prolonged in 14/29 SGPT: Raised in all <500 : 4 501-1000 :15 >1000 : 10

  13. Blood transfusion was given in 7 patients Vit K1 in therapeutic doses was given in 14 patients. Plasma required in 4 patients. Flumazenilgiven in 6 Patients * HAV+ve 3 Hbs Ag +ve 3 * among them stage II – 4 pt stage III – 2 pt * one child deteriorated others improved * Response was within 24 hrs max Treatment

  14. Expiry

  15. Conclusion • Incidence : 1.8/1000 in hospital . admission • Etiology: hepatitis B. A and other viral hepatitis - major .. causes • Early intensive care management… • Flumazenil - promising role but needs further evaluation.

More Related